Tag Archives: Scotland

Impact of pandemic The COVID-19 pandemic has brought this into even sharper focus, having had a significant impact on people with heart disease and on the services that support them. A recent study of severe COVID-19 cases across the UK revealed that the most common comorbidity is chronic heart disease (29%).6 Ischaemic (coronary) heart disease has been the second most common pre-existing condition for COVID-19 fatalities in Scotland, behind dementia and Alzheimer’s disease.7,8 Furthermore, during the initial lockdown period of the pandemic, overall attendance at Accident and Emergency (A&E) decreased,9 and this period coincided with a

Video of our webinar: Restarting cardiology services in Scotland in the COVID-19 era This webinar took place on Wednesday 16th September 2020. Watch our panel of experts discuss how we can start to optimally deliver key services in Scotland as the pandemic eases, as well as answer questions from the webinar participants. Learning objectives A review of the challenges of restarting cardiology services in the COVID-19 era Dealing with the backlog of coronary artery disease treatment The practicalities in restarting cardiac rhythm management Assessing new models of remote and self care in heart failure Is it for me? This webinar is aimed at a

Dr Sean L Zheng CVOTs The key studies evaluated sodium-glucose co-transporter 2 (SGLT2) inhibitors – empagliflozin (EMPA-REG OUTCOME)4 and canagliflozin (CANVAS)5 – and glucagon-like peptide 1 (GLP-1) receptor agonists – liraglutide (LEADER)6 and semaglutide (SUSTAIN-6)7 – in patients with type 2 diabetes and cardiovascular disease or elevated cardiovascular risk (table 1). In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) study, the use of empagliflozin resulted in 38% and 35% reductions in cardiovascular death and heart failure hospitalisation, r

No content available